U.S., Oct. 30 -- ClinicalTrials.gov registry received information related to the study (NCT07902817) titled 'A Phase 3 Blinded Study of JADE101 in Participants With Immunoglobulin A Nephropathy' on Oct. 22.
Brief Summary: This Phase 3 study will evaluate the safety and efficacy of JADE101 compared with placebo in adults with immunoglobulin A nephropathy (IgAN). The results will contribute to the overall clinical characterization of JADE101 in this patient population.
Study Start Date: Dec., 2026
Study Type: INTERVENTIONAL
Condition:
IgA Nephropathy (IgAN)
Intervention:
DRUG: JADE101
JADE101 is supplied as sterile solution to be administered by SC injection.
DRUG: Placebo
Placebo is supplied as sterile solution to be administered b...